



In Search of Excellence

**ORION PHARMA LIMITED**Register Office: Orion House, 153-154 Tejgaon I/A,  
Tejgaon, Dhaka-1208**UN-AUDITED HALF YEARLY (Q2) FINANCIAL STATEMENTS**

This is for the information of all concerned that the un-audited condensed consolidated financial statements of Orion Pharma Limited as on and for the Half Yearly (Q2) period ended on December 31, 2020, has been adopted by the Board of Directors in its meeting held on January 30, 2021. The excerpts of the Financial Statements are as follows:

<u>Particulars</u>	<u>December 31,</u> <u>2020</u>	<u>December 31,</u> <u>2019</u>
Consolidated Earnings Per Share (EPS)- Q2	BDT. 2.03	BDT. 2.14
Consolidated NAV per Share - Q2 (Including Revaluation Surplus)	BDT. 77.91	BDT. 75.73
Consolidated NAV per Share - Q2 (Excluding Revaluation Surplus)	BDT. 69.89	BDT. 67.58
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q2	BDT. 2.34	BDT. 3.11

The Detailed Financial Statements are also available in the Company's website: [www.orionpharmabd.com](http://www.orionpharmabd.com).

Sd/-  
Company SecretarySd/-  
Head of FinanceSd/-  
DirectorDated: Dhaka  
January 30, 2021Sd/-  
Managing DirectorSd/-  
Chairman